A large European trial found no survival benefit from using the LUCAS chest compression machine compared with manual compressions in patients with out-of-hospital cardiac arrest.
Research has shown that high-quality chest compressions save lives among cardiac arrest victims. In a manufacturer-sponsored, multicenter, European study, researchers randomly assigned 2589 adult patients with out-of-hospital cardiac arrest to receive manual or mechanical chest compressions.
Mechanical chest compressions were delivered by the LUCAS device, which is also approved in the U.S. The main outcome, 4-hour survival, was 24% in both groups. Secondary outcome measures (arrival at emergency department with palpable pulse; return of spontaneous circulation; survival with good neurological outcome at discharge, 1 month, and 6 months) also did not differ between groups.
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals